logo

For the Inventor, By the Inventor

Memphis, TN, United States of America

Shengdar Q Tsai

This inventor holds 20 USPTO granted patents and 2 published patent applications and 8 EPO patents, primarily in Genome Editing Technology. Top assignees: The General Hospital Corporation, St. Jude Children's Research Hospital. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shengdar Q Tsai. Retrieved from https://idiyas.com/inventor/shengdar-q-tsai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.3

ph-index = 10

Forward Citations = 373(Granted Patents)


Location History:

  • Charlestown, MA (US) (2017 - 2021)
  • Memphis, TN (US) (2017 - 2024)

Company Filing History:

goldMedal18 out of 3,073 
 
The General Hospital Corporation
 patents
silverMedal2 out of 281 
 
St. Jude Children's Research Hospital
 patents

Years Active: 2017-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Nuclease
Genome Editing
RNA-Guided
Homology-Directed Repair
FokI Nucleases
DSB Identification
High-Throughput
Cleavage Events
GUIDE-Seq
Change-Seq
CIRCLE-Seq
Multiplex Guide RNAs
20 patents (USPTO):Explore Patents
1. 12286641 - Methods for increasing efficiency of nuclease-induced homology-directed repair (2025-04-29),
2. 12104207 - Genomewide unbiased identification of DSBs evaluated by sequencing (GUIDE-Seq) (2024-10-01),
3. 11920152 - Increasing specificity for RNA-guided genome editing (2024-03-05),
4. 11371095 - High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro (Change-Seq) (2022-06-28),
5. 11098326 - Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing (2021-08-24),
6. 11028429 - Full interrogation of nuclease DSBs and sequencing (FIND-seq) (2021-06-08),
7. 11021718 - Methods for increasing efficiency of nuclease-induced homology-directed repair (2021-06-01),
8. 10920272 - High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro (2021-02-16),
9. 10844403 - Increasing specificity for RNA-guided genome editing (2020-11-24),
10. 10738303 - Comprehensive in vitro reporting of cleavage events by sequencing (CIRCLE-seq) (2020-08-11),
11. 10544433 - Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing (2020-01-28),
12. 10526589 - Multiplex guide RNAs (2020-01-07),
13. 10501794 - Genomewide unbiased identification of DSBs evaluated by sequencing (GUIDE-seq) (2019-12-10),
14. 10138476 - Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing (2018-11-27),
15. 10011850 - Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing (2018-07-03),

Title: **Shengdar Q Tsai: A Pioneer in Genome Editing Technologies**

Introduction

Shengdar Q Tsai is an innovative researcher and inventor based in Memphis, TN, with a remarkable portfolio of 19 patents. His groundbreaking work in the field of genome editing has paved the way for advancements in genetic research and therapy.

Latest Patents

Among his latest patents, Tsai has developed the "Genomewide unbiased identification of DSBs evaluated by sequencing (GUIDE-Seq)," which offers unbiased, genomewide, and highly sensitive methods for detecting mutations, including off-target mutations induced by engineered nucleases. Additionally, he has created methods for "Increasing specificity for RNA-guided genome editing," particularly in enhancing the accuracy of CRISPR/Cas9 systems, which are essential for precise genetic modifications.

Career Highlights

Tsai has worked with notable institutions, including the General Hospital Corporation and St. Jude Children's Research Hospital. His contributions to genetics and biotechnology have been instrumental in furthering our understanding of genome modification and its applications in medicine.

Collaborations

Throughout his career, Tsai has collaborated with prominent scientists such as J Keith Joung and James Angstman. These partnerships have fostered an environment of innovation and discovery, leading to advancements that benefit both the scientific community and public health.

Conclusion

Shengdar Q Tsai continues to be a driving force in the field of genome editing, with his discoveries and inventions shaping the future of genetic research. His dedication to innovation and collaboration positions him as a key figure in the evolution of biotechnology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…